Latuda generic launch date?

When can we expect the generic launch of Latuda?

Latuda, also known as Lurasidone, is an antipsychotic medication used to treat schizophrenia and depressive episodes associated with bipolar disorder. Developed by Sunovion Pharmaceuticals [1], the patent for Latuda is set to expire in 2027 [2] at the earliest. This timeline suggests that generic versions of the medication may become available after this date.

Who will manufacture the generics?

While there are several pharmaceutical companies that might develop and market generic versions of Latuda, it is impossible to determine with certainty which companies will be the first to market until patents are filed with the FDA and approved. Companies are actively developing generic versions of Latuda. We could expect to see applications submitted to the U.S. Food and Drug Administration by companies including Sandoz, Accord Healthcare, or Teva Pharmaceuticals, among others.

Will biosimilars be approved?

The U.S. Food and Drug Administration has a separate approval process for biosimilars (biological products similar to a licensed biologic product) rather than generics. While the agency typically approves biosimilars about 2 years sooner than the original patent expires for a traditional product, the timeline for biosimilars will rely heavily on their individual development and FDA review schedule.

Patent Expiration Timeline and Implications

Latuda was first approved in 2010. Given the patent expiration timeline of 2027, generic medications could potentially enter the U.S. market in 2028 or sooner, depending on the speed of FDA review for the generic products themselves. The generic market is typically characterized by intense competition, which may help lower prices and improve patient access.

Sources:

[1] DrugPatentWatch.com - Sunovion Pharmaceutical (Lurasidone)
https://www.drugpatentwatch.com/producer/Sunovion-Pharmaceuticals/US/

[2] DrugPatentWatch.com
https://www.drugpatentwatch.com/patent/Lurasidone

Additional Information:

It is crucial to note that actual market entry dates may vary based on several factors, including manufacturing and approval timelines, pricing strategies, and regulatory actions.